Recommended

Teva close to API business sale
Streamlined rAAV purification enables efficient upstream analytics – access now
First new IPF treatment in US for a decade
Webinar: Radiopharmaceuticals’ time-to-result challenge
AstraZeneca/Daiichi cancer drug boost
Takeda to move away from cell therapy
GSK appoints new CEO
news

Ipsen strikes €1bn deal to acquire French biotech ImCheck Therapeutics

0
SHARES

The move will boost its oncology pipeline, adding a potential first-in-class anti-BTN3A monoclonal antibody for acute myeloid leukaemia.

Ipsen ImCheck Therapeutics

Credit: HJBC / Shutterstock.com

Ipsen is set to acquire French biotech ImCheck Therapeutics in a move that will strengthen its oncology pipeline by adding rights to a potential first-in-class anti-BTN3A monoclonal antibody.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

ImCheck’s lead asset ICT01 is currently being evaluated in an ongoing phase I/II EVICTION trial in first line acute myeloid leukaemia (AML) patients who are ineligible for intensive chemotherapy.

The biologic’s unique mechanism of action modulates both innate and adaptive immunity and recent clinical data suggests that in combination with Ven-Aza (venetoclax and azacitidine) ICT01 has potential as a novel immunotherapy for AML. 

recent clinical data suggests that in combination with Ven-Aza (venetoclax and azacitidine) ICT01 has potential as a novel immunotherapy for AML”

David Loew, Ipsen’s CEO, said: “We feel confident that with the ICT01 promising data combined with Ipsen’s global development and commercialisation expertise, we are well positioned to start a phase IIb/III trial in 2026.” 

Interim data from the EVICTION trial, presented at the American Society of Clinical Oncology (ASCO) 2025 congress, showed that the combination therapy nearly doubled treatment response relative to historical standard of care data across all molecular subtypes in newly diagnosed patients.

The findings suggest that ICT01-mediated γ9δ2 T cell activation could be the first immunotherapeutic option for newly diagnosed AML patients ineligible for induction chemotherapy.

The deal is expected to close by the end of the first quarter of 2026 and will involve an initial €350 million to ImCheck Therapeutics shareholders, with total payments set to reach €1 billion if all milestones are met.

For Ipsen it adds to its July 2024 oncology licensing deal with Day One Biopharmaceuticals for rights to the kinase inhibitor tovorafenib in a paediatric indication. At the time of that announcement, like ICT01, tovorafenib was being investigated as a potential combination treatment.

Takeda also made a move this week to strengthen its oncology pipeline. Through a new partnership agreement with Innovent Biologics valued initially at $1.2 billion, Takeda could add a potential first-in-class antibody drug to its pipeline.

Share via
Share via